| Hazard Information | Back Directory | [Uses]
Gastrazole (JB95008) is potent and selective CCK2/gastrin receptor antagonist. Gastrazole can decrease the level of gastric acid. Gastrazole inhibits the Gastrin-stimulated growth of pancreatic cancer[1][2]. | [in vivo]
Gastrazole (0.15-3 μmol/kg; i.v.) dose-dependently inhibits the Pentagastrin-stimulated gastric acid secretion[2]. | Animal Model: | Male Sprague-Dawley rats with a gastric fistula[2] | | Dosage: | 0.15, 0.3, 3 mg/kg | | Administration: | Intravenous administration | | Result: | Dose-dependently inhibited Pentagastrin-stimulation acid secretion by maximally 73%. |
| [IC 50]
CCKBR | [References]
[1] Chau I, et, al. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br J Cancer. 2006 Apr 24;94(8):1107-15. DOI:10.1038/sj.bjc.6603058
[2] Rudholm T, et, al. Release of regulatory gut peptides somatostatin, neurotensin and vasoactive intestinal peptide by acid and hyperosmolal solutions in the intestine in conscious rats. Regul Pept. 2009 Jan 8;152(1-3):8-12. DOI:10.1016/j.regpep.2008.10.002 |
|
|